ArticleNature medicine2020
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
Abstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies.Microsystems & nanoengineering · 2022Article
- COVID-19: organoids go viral.Nature reviews. Molecular cell biology · 2020Article
Corrections and comments
- Erratum for
Authors and funding
35 authors.
Francesca Chemi *Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Dominic G Rothwell *Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Nicholas McGranahan *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sakshi GulatiClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Chris AbboshUniversity College London Cancer Institute, London, UK.
Simon P PearceClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.ORCID http://orcid.org/0000-0002-1680-5538
Cong ZhouClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Gareth A WilsonUniversity College London Cancer Institute, London, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nicolai BirkbakUniversity College London Cancer Institute, London, UK.
Jackie PierceClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Chang Sik KimClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Saba FerdousClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Deborah J BurtClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Daniel Slane-TanClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Fabio GomesCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
David MooreUniversity College London Cancer Institute, London, UK.
Rajesh ShahDepartment of Thoracic Surgery, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Crispin HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Selvaraju VeeriahUniversity College London Cancer Institute, London, UK.
Yvonne SummersDivision of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Philip CrosbieCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
Sophia WardCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Barbara MesquitaClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Marek DynowskiScientific Computing Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Dhruva BiswasCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-9141-5188
Jonathan TugwoodClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Fiona BlackhallCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
Crispin MillerRNA Biology, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Allan HackshawUniversity College London Cancer Institute, London, UK.
Ged BradyClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK. ged.brady@cruk.manchester.ac.uk.ORCID http://orcid.org/0000-0002-5009-8814
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. charles.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
Caroline DiveClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK. caroline.dive@cruk.manchester.ac.uk.ORCID http://orcid.org/0000-0002-1726-8850
TRACERx Consortium
Funding
Cancer Research UK 17786Cancer Research UK 21999Cancer Research UK 22246Cancer Research UK 28990Cancer Research UK 29420Cancer Research UK 29569Cancer Research UK 30025Cancer Research UK A27412
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Identifiers
PMID
32494064What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.